Matters of the Heart: Cardiac Toxicity of Adjuvant Systemic Therapy for Early-Stage Breast Cancer
Authors:
- P.L. BedardPBP.L. Bedard
- Sunil VermaSVSunil Verma
Open Access
- 1 January 2008
- journal article
- Published by MDPI AG in Current Oncology
- Vol. 15 (11) , 16-29
Abstract
Breast cancer remains the most common malignancy in women. Since the late 1980s, significant advances have been made in the treatment of this cancer. Those advances, particularly the ones in the adjuvant setting, have led to declines in the mortality associated with breast cancer. But another result has been treatments that are more complex and that potentially carry more toxicity. One key toxicity related to the adjuvant therapy of breast cancer is cardiac toxicity. Some of the agents commonly used for the treatment of breast cancer, including anthracyclines, trastuzumab, and possibly even aromatase inhibitors, have been associated with cardiac toxicity. The present article reviews the current understanding of cardiac toxicity risk and strategies to minimize cardiac morbidity associated with cytotoxic chemotherapy, trastuzumab therapy, and hormonal therapy with aromatase inhibitors for early-stage breast cancer.Keywords
This publication has 71 references indexed in Scilit:
- Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 TrialJournal of Clinical Oncology, 2007
- Different anthracycline derivates for reducing cardiotoxicity in cancer patients2006
- Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast CancerThe Oncologist, 2006
- Selection of adjuvant chemotherapy for treatment of node-positive breast cancerThe Lancet Oncology, 2005
- Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2005
- Bringing Molecular Prognosis and Prediction to the ClinicClinical Breast Cancer, 2005
- ErbB2 is essential in the prevention of dilated cardiomyopathyNature Medicine, 2002
- Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast IrradiationJournal of Clinical Oncology, 2001
- Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.1999
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987